Clinical trials: Eclampsia, Antepartum
Severe Preeclampsia
Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia
This study evaluates the use of AMAG-423 (Digoxin Immune Fab) in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.
- Trial name
- NCT03008616
- Testing
- AMAG-423 (digoxin immune fab)
- Where
- 18 sites in United States, Poland and 1 more
- Volunteers
- 58 people
- Sponsor
- AMAG Pharmaceuticals, Inc.